Drug Patents owned by Msd Merck Co

1. Drug name - DELSTRIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(9 years from now)

CN102971308B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

CN102971308A MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN201208211P4 MSD MERCK CO Non Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN311693B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034A1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

EP2552902B1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902A1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902A4 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034B1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine Nov, 2036

(14 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine Nov, 2036

(14 years from now)

More Information on Dosage
Strength Dosage Availability
100MG;300MG;300MG TABLET;ORAL Prescription

2. Drug name - EMEND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/KIT FOR SUSPENSION;ORAL Prescription

3. Drug name - PIFELTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(9 years from now)

CN102971308B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

CN102971308A MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN201208211P4 MSD MERCK CO Non Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN311693B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034A1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

EP2552902B1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902A1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902A4 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034B1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

Drugs and Companies using DORAVIRINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

4. Drug name - RECARBRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(7 years from now)

CN102827067A MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

CN102827067B MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

CN101918407A MSD MERCK CO Beta-1Actamase Inhibitors
Jan, 2029

(6 years from now)

CN101918407B MSD MERCK CO Beta-Lactam Enzyme Inhibitor
Jan, 2029

(6 years from now)

IN201003977P4 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

IN293446B MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2231667A2 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2666774B1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2666774A1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2231667B1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.